HomeStocksAPLLTD

A

Alembic Pharmaceuticals

APLLTD Share PriceHealthcare

₹ 799.55

-8.65 (-1.07%)loss
as on 07 Sep 2026 at 03:51 PM
views8
portfolio639
analyst55.56% Hold
Overview
Pros & Cons
News
History
Fundamentals
Investment Returns
Technicals
Financials
Balance Sheet
Cash Flow
Corporate Actions
Peers

Alembic Pharmaceuticals Share Price Today

Today Alembic Pharmaceuticals opened at 808.00 while its previous close was at 808.20. In todays trading session APLLTD reached a high of 828.10 and low of 797.40. The average traded price for today is 808.96. The 50 DMA stands at 821.60 and 200 DMA is at 789.35. Looking at intraday trend, the stock is in Downtrend.

50 DMA: 821.60200 DMA: 789.35
chartsarrowTradingViewarrow

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

Use Chart

APLLTD Stock Performance

Markets Today

High

828.10

Low

797.40

Open at

808.00

Prev Close

808.20

Volumes

1,71,275

Avg Price

808.96

Lower Circuit

639.65

Upper Circuit

959.45

Last Traded Details

Quantity

4

Time

15:51:43

Price Movement

797.40828.10
0.27%Loss
down side
up side
3.45%Profit

Historical Performance

3 M High

859.00

3 M Low

717.40

1 Yr High

998.00

1 Yr Low

635.80

3 Yr High

1,303.90

3 Yr Low

635.80

5 Yr High

1,303.90

5 Yr Low

462.30

1-Year Performance

635.80998.00
25.75%Loss
down side
up side
19.88%Profit
View In-Deptharrow

APLLTD Pros and Cons

byfuzz AI

US Business Revenue grows from ₹5.64 Cr in Q4 FY26 to ₹7.78 Cr in Q1 2026-27, reflecting strong commercial execution.

Consolidated ANDA Approvals rise from 4 in Q4 FY26 to 10 in Q1 2026-27, accelerating the US regulatory pipeline.

ISOFIT SR Market Share jumps from 14.5% in Q4 FY26 to 35.1% in Q1 2026-27, capturing significant category demand.

ALTHROCIN Market Share recovers from 84.2% in Q4 FY26 to 87.8% in Q1 2026-27, retaining dominant market positioning.

Total Income climbs from ₹18.73 Cr in Q4 FY26 to ₹21.65 Cr in Q1 2026-27, supporting overall top-line expansion.

Gross Margin compresses from 73% in Q2 FY26 to 71% in Q1 2026-27, signaling pricing or mix headwinds.

PAT Margin falls from 11% in Q4 FY26 to 8% in Q1 2026-27, indicating profit volatility despite revenue growth.

Material Consumption spikes from ₹5.32 Cr in Q4 FY26 to ₹6.20 Cr in Q1 2026-27, driven by higher production volumes.

India Branded Business Market Share slips from 1.3% in Q1 FY26 to 1.1% in Q1 2026-27, reflecting broader competitive pressure.

BLADMIR Market Share drops from 8.8% in Q4 FY26 to 6.5% in Q1 2026-27, showing recent category weakness.

fuzz Insights
Positive

Animal health sales stay strong by shifting to feed supplements.

Neutral

Profits look stable. But that's the tax refund talking, not the factory.

Neutral

US sales are booming, but overall profits are shrinking.

Neutral

API sales are growing, but raw material costs are dragging the group down.

Negative

Sales are climbing fast, but raw material costs are eating the gains.

Negative

More sales reps are on the ground, but market share is still slipping.

APLLTD Analyst Rating

Hold

Analysts have suggested that investors can Hold this Stock

- By Refinitiv from 9 analysts

Buy

44.44%

Hold

55.56%

Sell

0%

Get forecast for Price, ROA & ROE based on analyst ratings.

Get Forecast

APLLTD Latest News

View Allarrow

APLLTD Share Price History

View In-Deptharrow

APLLTD Fundamentals

Company Valuation

Market Cap (₹ Cr.)

15,716

PE Ratio

23.00

PB Ratio

2.80

Dividend Yield

1.48%

ROE

11.83%

ROCE

12.77%

Book Value (₹)

288.70

Face Value (₹)

2.00

Analyse APLLTD with 12+ custom fundamentals and financial ratios.

Analyse Now

Share Holding Pattern

Held ByJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
69.67%69.74%69.74%69.74%69.87%
Domestic Institutional Investors (DII)
16.46%16.30%16.17%16.18%15.94%
Foreign Institutional Investors (FII)
3.96%4.05%4.24%4.25%4.18%
Public Investors
7.01%6.93%6.87%6.86%6.97%
Government
0.00%0.00%0.00%0.00%0.00%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government

View In-Deptharrow

Alembic Pharmaceuticals Return Calculator

You have invested
Investment Period

Current value of ₹1,00,000 invested 5 years ago, as on today

₹ 0

Gain

₹ 1,00,000 (4.32%)

Invest Now

Note: Past profits do not guarantee future returns.

APLLTD Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

View In-Deptharrow

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.

Start SIP

APLLTD Technicals

Moving Averages

PeriodSimpleSignal
5-SMA823.50Bearish
10-SMA819.98Bearish
20-SMA823.72Bearish
50-SMA821.60Bearish
100-SMA789.07Bullish
200-SMA789.35Bullish

Technical Indicators

IndicatorValueAction
RSI(14)45.81Neutral
ATR(14)23.33Less Volatile
STOCH(9,6)43.08Neutral
STOCH RSI(14)27.30Neutral
MACD(12,26)-1.91Bearish
ADX(14)14.44Weak Trend

Summary of Technical Indicators for APLLTD

View In-Deptharrow

Margin on APLLTD

Order TypeMargin to PayLeverageQuantityTrade ValueMargin AmountActions

*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).

APLLTD Financials Summary

View By:
Revenue
EBITDA
Net Profit
EPS
Revenue

In Crores

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,7171,9191,8921,8742,165

APLLTD Financials

View by

Income Statement

In Cr

Quarterly StatementJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,7171,9191,8921,8742,165
Expenses1,4301,5951,6271,6451,818
287324265230347
Operating Profit281316249203332
Operating Profit Margin %16%17%13%11%15%
Other Income78162715
Interest2424232328
Depreciation7476808998
190224162119222
Tax %19%18%18%-70%22%
Net Profit154184132202172
EPS897109

Balance Sheet

In Cr

Yearly Balance SheetMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7,1226,1836,4467,7738,763
Fixed Assets1,7982,3982,5472,5243,081
Current Assets2,8612,9103,0794,0884,543
Capital Work in Progress2,304601524837683
Investments1189693127141
Other Assets2,9023,0873,2824,2854,858
7,1226,1836,4467,7738,763
Current Liabilities1,7171,6371,4552,4122,594
Non Current Liabilities168175172171500
5,2384,3714,8185,1905,669
Reserve & Surplus5,1984,3314,7795,1525,636
Share Capital3939393939
Minority Interest000-1-6

Cash Flow

In Cr

Yearly Cash FlowMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Activities55272480388783
Investing Activities-372-448-321-568-506
Financing Activities-217-262-438444-164
Net Cash Flow-371445-37113
View In-Deptharrow

Corporate Actions

DateCorporate ActionInformation
4th Aug 2026, Tuesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q1 FY 26-27 Results
info
29th Jul 2026, Wednesday
DIVIDENDDividend
Final Dividend of ₹12/share
15th May 2026, Friday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q4 FY 26-27 Results
info
5th Feb 2026, Thursday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q3 FY 25-26 Results
info
4th Nov 2025, Tuesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q2 FY 25-26 Results
info

The above dates are ex-dates.

View Allarrow

Check APLLTD latest Company Filings, Investor Presentation & Conference Call details.

Read Now

APLLTD Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2025-266,707
10.31% profit
640
27.29% profit
FY 2024-256,081
2.97% profit
503
-24.51% Loss
FY 2023-245,905
14.61% profit
667
92.22% profit

Top Mutual Funds Invested in APLLTD

APLLTD Popular Brands

APLLTD Similar Stocks

Stock NamePrice
Sun Pharmaceutical

S

Sun Pharmaceutical

1,895.00-0.21%loss
Divis Laboratories

D

Divis Laboratories

9,315.00+2.36%profit
Torrent Pharmaceuticals

T

Torrent Pharmaceuticals

4,914.00+1.17%profit
Zydus Life Science

Z

Zydus Life Science

1,156.90+3.29%profit
Cipla

C

Cipla

1,395.00+0.72%profit
View Allarrow

NSE Indices Today

Index NamePrice
View Allarrow

Top Gainers Today

Stock NamePrice
View Allarrow

Top Losers Today

Stock NamePrice
View Allarrow

Open IPOs

View All IPOsarrow

Calculators

Brokerage Calculator

Brokerage Calculator

Margin Calculator

Margin Calculator

MTF Calculator

MTF Calculator

Stock Return Calculator

Stock Return Calculator

Stock Average Calculator

Stock Average Calculator

View Allarrow

What's New In The Market

View Allarrow

FAQs on APLLTD

Alembic Pharmaceuticals share price as of today is ₹ 799.55 as on 07 Sep 2026 at 03:51 PM.
The 52W high of Alembic Pharmaceuticals is ₹ 998.00 and 52W low is ₹ 635.80 as of 07 Sep 2026 at 15:51.
The past returns of Alembic Pharmaceuticals share are -
  • Past 1 year: -16.72%
  • Past 3 years: 3.82%
  • Past 5 years: 4.32%
The PE and PB ratio of Alembic Pharmaceuticals stands at 23.00 and 2.80 respectively as on 07 Sep 2026 at 15:51.
The EPS of Alembic Pharmaceuticals is 8.80 for the quarter ended Jun 2026 and 34.33 for the financial year 2025-26.
The shareholding pattern of Alembic Pharmaceuticals is as follows:
  • DIIs - 15.94%
  • FII - 4.18%
  • Promoters - 69.87%
  • Public Investors 6.97%
  • Goverenment - 0.00%
Yes, you can buy shares of Alembic Pharmaceuticals online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Alembic Pharmaceuticals stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Alembic Pharmaceuticals share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Alembic Pharmaceuticals.
You can easily buy the shares of Alembic Pharmaceuticals even after the markets are closed using the After Market Order feature on Dhan Trading App.


Invest & Trade with a Trading
Platform That's icon

Open your Dhan Account in minutes!


border
logo

Join our Community

community logo

Follow us on

twitter
telegram
Linkedin
youtube
instagram
facebook

built with love
for Indians who love to invest & trade

raise

We are part of Raise Financial Services

raise
raise

Explore  |  Sitemap


*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

We are doing so by giving you access to not just one but 6 products within the Dhan ecosystem:


This means that with Dhan, you'll be able to start:


Lakhs of users already trust Dhan for their online stock trading and investing needs. Dhan is growing rapidly because of the love we receive from SuperTraders and Long-Term Investors who acknowledge that the platform is innovating for them, building super useful features that help them do everything from investing in stock market to trading F&O like a pro on the Tradingview charts and much more.

While we are growing, we will always remember why we started building in the first place - you. Our user-first approach will always be at the heart of our philosophy. Come join us on this incredible journey!

Try it out, you can close your account at anytime using this link.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.

Details of client bank account

For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution